Cellectis announced that an arbitral tribunal issued a decision on December 15, 2025, which was made public on December 16, 2025. The ruling partially terminates the existing license agreement with Servier for the UCART19 V1 product (also known as ALLO‑501) and requires Cellectis to engage in good‑faith discussions with Allogene Therapeutics about a direct license for the same asset.
The partial termination removes Servier’s exclusive rights to UCART19 V1, a product that Allogene had already discontinued in 2021 in favor of its own cema‑cel platform. By ending Servier’s claim, Cellectis gains the opportunity to negotiate a direct license with Allogene, potentially restoring control over the asset and allowing the company to pursue its own development and commercialization strategy for UCART19 V1.
From a business perspective, the decision is a mixed outcome. On one hand, the loss of the license agreement could be viewed as a setback for UCART19 V1, but the ability to negotiate a direct license mitigates that risk and may enable Cellectis to secure more favorable terms. The ruling also clears a path for the company to focus on its broader pipeline, which includes several other cell‑therapy candidates that are not affected by the Servier dispute.
The tribunal’s decision does not resolve the broader Servier licensing dispute, leaving open the possibility of further legal or commercial negotiations. Cellectis will need to monitor subsequent developments, as any additional rulings could impact its strategic positioning and revenue projections for the coming years.
Investors have reacted to the partial termination as a negative signal for UCART19 V1, reflecting concerns about the loss of a previously secured license. However, the potential for a direct license agreement is viewed as a mitigating factor that could preserve future revenue streams for the asset.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.